A sharp surge in platinum prices is threatening to significantly increase the cost of essential cancer treatments, with pharmaceutical companies in India seeking up to a 50% hike in drug prices. The move could put additional financial pressure on patients who rely on these life-saving medicines.
Manufacturers Seek Price Revision
Domestic drugmakers have approached the National Pharmaceutical Pricing Authority (NPPA), stating that producing key chemotherapy drugs—such as carboplatin, cisplatin, and oxaliplatin—has become financially unsustainable. These medicines rely heavily on platinum, a critical raw material whose price has seen a steep rise in recent months.
At present, carboplatin is capped at around ₹61.10 per 10 mg/ml vial, while cisplatin prices range between ₹70 and ₹300 depending on dosage. Major pharmaceutical firms including Cipla, Dr. Reddy’s Laboratories, Zydus Lifesciences, and others are among those impacted.
Platinum Prices Nearly Double
Industry sources indicate that platinum prices have nearly doubled over the past six months due to global geopolitical uncertainties. Prices have surged from approximately ₹3,869 per gram last September to nearly ₹8,000 per gram by February. Although prices have shown signs of stabilizing, they remain historically high, squeezing manufacturers’ margins.
Executives warn that without government intervention, the production of these essential drugs may become unviable, potentially affecting their availability in the market.
A Critical Component of Cancer Treatment
Medical experts emphasize that platinum-based drugs form the backbone of treatment for several cancers, including breast, head and neck, ovarian, and gastrointestinal cancers. Known for their affordability compared to newer therapies like immunotherapy and antibody-drug conjugates, these drugs are widely used in India and globally.
However, their low pricing—once seen as an advantage—is now creating a paradox. With limited profit margins, companies may lose incentive to continue production, risking supply shortages.
Market Size and Growing Demand
The market for platinum-based cancer drugs in India is estimated at around ₹110 crore and is growing at an annual rate of 14%. Experts believe that with rising cancer cases, demand could increase significantly in the coming years.
Call for Government Intervention
Price controls on these medicines have been in place since 2013, with only modest increases over the years. Industry stakeholders are urging authorities to consider revising the price caps, pointing to earlier recommendations by NITI Aayog in 2019, which supported price hikes for essential medicines deemed economically unviable.
As discussions continue, the outcome will be crucial in balancing affordability for patients and sustainability for manufacturers—both vital to ensuring uninterrupted access to critical cancer treatments.
